By Benjamin Horney (November 20, 2015, 6:23 PM EST) -- Pfizer Inc. and Allergan PLC have agreed on what roles certain executives would take in a combined company, according to a Friday report from Reuters, potentially removing "one of the last" obstacles to getting regulatory approval. According to the report, Pfizer CEO Ian Read would retain that title, with Allergan CEO Brent Saunders assuming "another very senior role." A announcement of the rumored megadeal is expected within the next few days, the report added. Just yesterday reports said the duo were closing in on a deal that could see the Pfizer pay up to $150 billion for the Irish drugmaker. The two companies confirmed in late October that they were in talks concerning a potential deal, though at that time they described it as "preliminary friendly discussions." Bringing together Allergan and Pfizer would create a pharmaceutical behemoth with a combined market capitalization of nearly $340 billion....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
